NCT00966940

Efficacy and Safety of Travoprost 0.004% Versus Tafluprost 0.0015% in Patients With Primary Open-angle Glaucoma or Ocular Hypertension

The Efficacy and Safety of Travoprost, 0.004% Versus Tafluprost, 0.0015% in Primary Open-Angle Glaucoma or Ocular Hypertensive Patients

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 51 (actual)
• Sponsor: Alcon Research · Industry
• Sex: All
• Age: 21 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to assess the safety and efficacy of Travoprost 0.004% and Tafluprost 0.0015% in patients with primary open angle glaucoma or ocular hypertension when both medications are administered in the evening.

Conditions

• Glaucoma

Interventions

Type	Name	Description
DRUG	Travoprost 0.004% ophthalmic solution (TRAVATAN)	One drop in the qualifying eye(s) each evening at 6:00 PM for 6 weeks, topical administration
DRUG	Tafluprost 0.0015% ophthalmic solution	One drop in the qualifying eye(s) each evening at 6:00 PM for 6 weeks, topical administration

Timeline

• Start date: 2009-09-01
• Primary completion: 2010-03-01
• Completion: 2010-03-01
• First posted: 2009-08-27
• Last updated: 2012-06-20
• Results posted: 2012-06-20